"I can honestly say, in the three years we have been on the market, we haven't received that many phone calls (about lumping)," Lalonde says.
De Lorenzi says he is offended by Canderm's suggestion that he has a conflict of interest regarding Artecoll, since he is working on a Q-MED-funded study of two other products.
"They're belittling me," he says. "In my business there's a hell of a lot of easier ways to make money than to go into some kind of corporate pissing match with some company."
Canderm officials "can say whatever the hell they want," De Lorenzi says. "The chips are going to fall and it's not going to be on me."
There's no stress placed on a lumping risk in Canderm pamphlets and other consumer information aimed at the general public. Instead, on its Web site and in printed handouts, the company makes a sweeping claim regarding a kind of inflamed lump called a granuloma: "Since Artecoll was introduced on the Canadian market in August, 1998, no incidences (of granuloma) have been reported."
Some of the links that appear in this article may have been sponsored by a third-party for commercial purposes.
This information is not to substitute for professional medical advice. You
should not use this information to diagnose or treat a health problem or
disease without consulting with a qualified healthcare provider. Please
consult your healthcare provider with any questions or concerns you may have
regarding your condition.
